Spyre Therapeutics details ECCO presentations and SPY003 Phase 1 follow-up

Spyre Therapeutics announced scientific presentations at the 21st Congress of the European Crohn’s and Colitis Organisation (ECCO), held February 18-21, 2026 in Stockholm, Sweden. The presentations included follow-up data out to 20 weeks from its Phase 1 study of SPY003 and details of the SKYLINE-UC platform study in ulcerative colitis. The company is also seeking to raise $403 million through a follow-on stock offering of 6.5 million shares priced at $62 per share.

The company said the data showed SPY003 was well tolerated, had a differentiated PK profile supporting quarterly or twice-yearly dosing, and demonstrated targeted biological activity via a reduction in downstream cytokines. One poster was titled, "Interim Phase 1 Results for SPY003, a Novel Half-Life Extended Monoclonal Antibody Targeting IL-23, Suggest Potential for Q3M or Q6M Maintenance Dosing for Inflammatory Bowel Disease."

A second poster was titled, "SKYLINE-UC: the First Platform Study in Ulcerative Colitis Assessing Efficacy and Safety of Three Long-acting Antibodies Administered as Single Agents and in Combinations." A third poster was titled, "Anti-TL1A and Anti-IL-23 Combination Therapy is Superior to its Constituent Monotherapies in Mouse Anti-CD40 Colitis."

Spyre Therapeutics is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations for inflammatory bowel disease and rheumatic diseases. Spyre's pipeline includes investigational extended half-life antibodies targeting α4β7, TL1A, and IL-23. Spyre’s lead candidate is SPY001, in Phase II for treating ulcerative colitis.